We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Circulating DNA Distinguishes Benign from Malignant Prostate Disease

By LabMedica International staff writers
Posted on 16 Nov 2010
Free circulating DNA (fcDNA) that has been released into the blood after tumor cell death can be measured as a biomarker for cancer. More...


In patients with prostate cancer (CaP), increased fcDNA is found in men with metastatic CaP as compared to controls, but not in men with localized CaP. Serum fcDNA can be measured by real-time polymerase chain reaction for the glutathione S-transferase, pi gene (GSTP1). GSTP1 variant proteins are thought to function in xenobiotic metabolism and play a role in susceptibility to cancer, and other diseases

Scientists at the University of Miami (Miami, FL, USA) prospectively evaluated fcDNA in 252 men who have undergone CaP screening and prostate biopsy to correlate levels in relation to the demographic and clinicopathologic features. Among the patients in the study, at prostate biopsy, 89 had CaP, 59 had prostatitis, and 104 had benign prostatic hyperplasia (BPH). The median fcDNA levels for CaP, BPH and prostatitis were 149 ng/mL, 96.9 ng/mL, and 81.8 ng/mL, respectively. There was no statistical difference between prostatitis and BPH regarding fcDNA levels, but the difference was statistically significant for CaP versus benign etiologies.

When stratified by total prostate specific antigen (PSA) levels, the results showed that for patients with a PSA of less than 10 ng/mL, the difference remained significant. However, there was no significant difference in fcDNA levels for CaP versus benign causes in patients with PSA greater than 10 ng/mL. An interaction between fcDNA and PSA yielded a high negative predictive value of 93.1% and increased specificity of 33.1% compared with negative predictive value of 73.3% and specificity of 6.7% in the model excluding fcDNA. Prostate cancer was diagnosed in 35.3% of the patients whose mean age was 66 years, compared with 63 years in both prostatitis patients and in BPH patients. The CaP group had a significantly higher percentage of African-American patients (48%) compared with prostatitis (17%).

The authors stated that the main inference from the study was that by adding fcDNA to prostate cancer screening the number of unnecessary prostate biopsies can be reduced. The study was published in August 2010, in the journal Cancer Epidemiology and Biomarkers Prevention.

Related Links:

University of Miami




New
Gold Member
Hematology Analyzer
Medonic M32B
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: A diagnostic test can distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone (Photo courtesy of University of Turku)

Novel Diagnostic Tool to Revolutionize Treatment Guidance of Head and Neck Cancer

Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type commonly treated with surgery. However, there has been no clinically available method to determine which patients can be cured with surgery... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.